Given that AR loss is a key feature of therapy-resistant PCa, this model allowed us to examine whether NO’s ability to regulate ER stress and inhibit tumor growth is consistent in AR-negative prostate cancer cells. The gene discussed is AR; the disease is prostate carcinoma.